GENENTA SCIENCE S.P.A.

(GNTA)
  Report
Delayed Nasdaq  -  11:18 2022-06-27 am EDT
7.950 USD   +2.61%
06/14Certain Ordinary Shares of Genenta Science S.p.A. are subject to a Lock-Up Agreement Ending on 14-JUN-2022.
CI
05/17European ADRs Move Higher in Tuesday Trading
MT
05/13Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Decline in Wednesday Trading

05/04/2022 | 12:08pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACHILLES CORPORATION 1.56% 1370 Delayed Quote.8.01%
ACHILLES THERAPEUTICS PLC -1.93% 2.54 Delayed Quote.-48.30%
AKARI THERAPEUTICS, PLC -1.01% 0.98 Delayed Quote.-34.00%
AMARIN CORPORATION PLC 0.00% 1.92 Delayed Quote.-43.03%
AUTOLUS THERAPEUTICS PLC 8.17% 2.78 Delayed Quote.-50.48%
BRITISH AMERICAN TOBACCO PLC 1.16% 3571.5 Delayed Quote.29.23%
CELLECTIS S.A. 4.53% 2.952 Real-time Quote.-62.04%
DBV TECHNOLOGIES -0.63% 4.448 Real-time Quote.46.32%
EQUINOR ASA 3.01% 334 Real-time Quote.37.45%
GENENTA SCIENCE S.P.A. 2.61% 7.95 Delayed Quote.-29.32%
HSBC HOLDINGS PLC 0.24% 538.6 Delayed Quote.19.74%
MYT NETHERLANDS PARENT B.V. -0.72% 10.99 Delayed Quote.-47.81%
NORWEGIAN ENERGY COMPANY ASA 1.83% 333 Real-time Quote.112.89%
OLINK HOLDING AB (PUBL) -3.53% 12.01 Delayed Quote.-31.59%
ORCHARD THERAPEUTICS PLC 5.15% 0.5783 Delayed Quote.-58.33%
SEQUANS COMMUNICATIONS S.A. 0.06% 2.6115 Delayed Quote.-44.94%
SILENCE THERAPEUTICS PLC -62.96% 2.5 Delayed Quote.0.00%
TELECOM ITALIA S.P.A. -1.26% 0.2576 Delayed Quote.-39.91%
All news about GENENTA SCIENCE S.P.A.
06/14Certain Ordinary Shares of Genenta Science S.p.A. are subject to a Lock-Up Agreement En..
CI
05/17European ADRs Move Higher in Tuesday Trading
MT
05/13Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
AQ
05/09Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
AQ
05/04Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
AQ
05/04European ADRs Decline in Wednesday Trading
MT
05/04Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial..
AQ
05/04Genenta Science S.P.A. Announces Ongoing Trial of Temferon™
CI
05/02Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblasto..
AQ
05/02Genenta Science Announces Preliminary Findings from its Phase 1/2A of Temferon™ in..
CI
More news
Analyst Recommendations on GENENTA SCIENCE S.P.A.
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -19,2 M -20,4 M -20,4 M
Net Debt 2022 - - -
P/E ratio 2022 -8,33x
Yield 2022 -
Capitalization 136 M 145 M 145 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 4
Free-Float 21,0%
Chart GENENTA SCIENCE S.P.A.
Duration : Period :
Genenta Science S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 7,49 €
Average target price 20,94 €
Spread / Average Target 179%
EPS Revisions
Managers and Directors
Pierluigi Paracchi Chief Executive Officer & Director
Richard B. Slansky Chief Financial Officer
Mark A. Sirgo Chairman
Carlo Russo Chief Medical Officer & Head-Development
Roger Abravanel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENENTA SCIENCE S.P.A.-29.32%141
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-11.36%18 371